mass spectrometry comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-01-15. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status: AOD-9604 is not approved as a therapeutic drug in the United States, European Union, or other major markets. It is listed by the World Anti-Doping Agency as a prohibited substance in sport, specifically under growth hormone fragments. Many jurisdictions restrict its sale for human consumption. Products marketed online may not meet pharmaceutical quality standards. The legal status varies by country and often depends on whether the material is presented as a research chemical, supplement, or drug.
Detection and characterization of AOD-9604 in research and anti-doping settings typically rely on mass spectrometry coupled with liquid chromatography. These methods can identify the peptide by its mass and fragmentation pattern. Immunoassays may also be used in some screening contexts, but they can cross-react with related peptides. Because the molecule is small and may be present at low concentrations, sample preparation and method validation are important. Confirmatory analysis usually requires comparison with a certified reference standard.
In laboratory settings, AOD-9604 is commonly supplied as a lyophilized powder and stored cold to limit degradation. Reconstituted solutions are typically kept refrigerated or frozen, depending on the buffer and concentration, and protected from repeated freeze-thaw cycles. Stability can be influenced by pH, temperature, and the presence of proteases. Purity is usually assessed by high-performance liquid chromatography and mass spectrometry. These practices support reproducibility, but they do not imply safety or efficacy for any human use.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved as a medicine | Status varies by country; prohibited in sport. |
| Common storage temperature | 2–8 °C for lyophilized powder | Protect from light and moisture; follow supplier instructions. |
| Typical analytical method | LC-MS/MS | Used for identification and quantification in biological samples. |
| Purity assessment | HPLC and mass spectrometry | Reverse-phase HPLC is common for peptide purity. |
| Common synonyms | AOD9604; hGH 176-191 fragment | Naming conventions differ across studies. |
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
The peptide is frequently described as a growth hormone fragment, although it is chemically distinct from full-length hGH. AOD-9604 contains 16 amino acids and includes two cysteine residues that can form an intramolecular disulfide bond. In solution, this structural feature can influence folding, aggregation, and stability. Published descriptions sometimes call it hGH 176-191 or AOD9604, with spacing and capitalization varying. Such naming differences can complicate literature searches, database entries, and product verification.
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
==== Supreme Court of Masonic Justice expels members ==== In June 2026, the Supreme Court of Masonic Justice permanently expelled eight members from the Grand Lodge and Supreme Council of Cuba, stripping them of their Masonic rights and privileges. Among those members expelled were;
=== Hyperbaric oxygen === In 2015, a Cochrane review concluded that for people with diabetic foot ulcers, hyperbaric oxygen therapy reduced the risk of amputation and may improve the healing at 6 weeks. However, there was no benefit at one year, and the quality of the reviewed trials was inadequate to draw strong conclusions.
The end of the Cold War allowed many technologies that had been off limits to the public to be declassified. The most important of these is the Internet, which was created as ARPANET as a system to keep in touch after an impending nuclear war. The last restrictions on commercial enterprise online were lifted in 1995. The commercialization of the Internet and the growth of the mobile phone system increased globalization (as well as nationalism and populism in reaction). In the years since then, the Internet's population and usefulness have grown immensely. Only about 20 million people (less than 0.5 percent of the world's population at the time) were online in 1995, mostly in the United States and several other Western countries. By the mid-2010s, more than a third of the world's population was online. Further research continued into other Cold War technologies with the declassification of the Internet. While Ronald Reagan's Strategic Defense Initiative proved untenable in its original form, the system lives on in a redesigned state as the Aegis Ballistic Missile Defense System (BMDS). Countermeasures such as BMDS continue to be explored and improved upon post–Cold War, but are often criticized for being unable to effectively stop a full nuclear attack. Despite advances in their efficacy, anti-ballistic missiles are often viewed as an additional piece to modern day diplomacy where concepts such as mutual assured destruction and treaties such as that between Ronald Reagan and Mikhail Gorbachev following their Reykjavík Summit.
Sources: en.wikipedia.org
Moreover, the apparent effect of PPIs cannot be caused by publication bias, according to a meta-analysis on 49 studies (2009). PPIs studied included producing gratitude letters, performing optimistic thinking, replaying positive life experiences, and socializing with people. Also, in a newer meta-analysis (39 studies, 6,139 participants, 2012), the standardized mean difference was 0.34 higher for subjective well-being, 0.20 for psychological well-being and 0.23 for depression. Three to six months after the intervention, the effects for subjective well-being and psychological well-being were still significant, so effects seem fairly sustainable. However, in high-quality studies, the positive effect was weaker, though positive, so authors considered further high-quality studies necessary to strengthen the evidence. They claimed that the above-mentioned meta-analysis (2009) did not put enough weight on the quality of studies. PPIs found positive included blessings, kindness practices, taking personal goals, and showing gratitude. The interventions called "Gratitude Journaling" and "Three Good Things" seem to operate via gratitude. There is evidence that, when gratitude journaling, focussing on quality over quantity as well as people more than possessions, yields greater benefits. There is also evidence of a diminished effect from gratitude journaling if it is done more than once or twice a week.
The chemical ecology of plant-insect interaction is a significant subfield of chemical ecology. In particular, plants and insects are often involved in a chemical evolutionary arms race. As plants develop chemical defenses to herbivory, insects which feed on them co-evolved to develop immunity to these poisons, and in some cases, repurpose these poisons for their own chemical defense against predators. For example, caterpillars of the monarch butterfly sequester cardenolide toxins from their milkweed host-plants and are able to use them as an anti-predator defense. Whereas most insects are killed by cardenolides, which are potent inhibitors of the Na+/K+-ATPase, monarchs have evolved resistance to the toxin over their long evolutionary history with milkweeds. Other examples of sequestration include the tobacco hornworm Manduca sexta, which use nicotine sequestered from tobacco plants in predator defense; and the bella moth, which secretes a quinone-containing froth to deter predators obtained from feeding on Crotalaria plants as a caterpillar. Chemical ecologists also study chemical interactions involved in indirect defenses of plants, such as the attraction of predators and parasitoids through herbivore-induced volatile organic compounds (VOCs).
== Post-playing career == On April 9, 2022, the Colorado Rockies hired Helton as a special assistant to the general manager, joining Vinny Castilla and Clint Hurdle in the role. They and Charlie Blackmon held that role in 2025.
=== Low-intensity conflict (8 April – 24 May) === On 8 April, the Taliban-run Afghan foreign ministry stated that talks with Pakistani officials in China had concluded and described the discussions as constructive. Chinese officials said that representatives of Pakistan and the Taliban had agreed to work toward an early easing of tensions and to avoid actions that could escalate the situation. Pakistani officials did not comment on the outcome of talks. On the same day, Amir Khan Muttaqi, the Taliban's foreign minister, said while meeting with diplomats from Central Asian states that the group would not permit Afghan territory to be used by any group to threaten neighboring states. Although he did not name any organisation, he said the presence of such elements anywhere was unacceptable and that the Taliban intended to deal with the matter. He also stated that the Taliban were committed to easing tensions with Pakistan through dialogue and said he hoped the talks would produce positive outcomes. However, on 9 April, Mohammad Naeem Wardak, the Taliban's deputy foreign minister, said that talks between Pakistani and Taliban officials in China had ended without agreement and attributed their failure to Pakistani officials. On 10 April, local elders in Kunar and Nuristan said that Taliban border forces had withdrawn from several border posts in Bari Kot in Nari district, Kunar, and in Kamdesh district, Nuristan, and had taken shelter in village mosques.
Sources: en.wikipedia.org
No major regulatory agency has approved AOD-9604 as a medicine. It is treated as an experimental peptide in research settings. Some countries restrict its sale or import.
The World Anti-Doping Agency classifies growth hormone fragments, including AOD-9604, as prohibited substances. The classification reflects concern about potential performance-enhancing use. Athletes are subject to testing for such peptides.
Detection typically uses liquid chromatography combined with mass spectrometry. These methods separate the peptide and identify it by mass. Immunoassays may screen samples but require confirmation by a more specific technique.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.